Inspire Medical Systems, Inc. Announces Updates from International Surgical Sleep Society and American Academy of Otolaryngology – Head and Neck Surgery Meetings
14 Setembro 2022 - 9:00AM
Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical
technology company focused on the development and commercialization
of innovative, minimally invasive solutions for patients with
obstructive sleep apnea, announced today key updates from the
International Surgical Sleep Society (ISSS) and American Academy of
Otolaryngology (AAO-HNSF) meetings which took place in Philadelphia
September 9-14th.
“We were excited to return to in-person conferences and
highlight our recent innovative technology enhancements to the
Inspire platform and share compelling clinical data further
demonstrating the real-world efficacy of our treatment,” said Tim
Herbert, President and CEO. “Inspire is a proud partner and sponsor
of ISSS, the world’s preeminent organization dedicated to the
surgical evaluation and treatment of patients with sleep disorders,
and AAO-HNSF, one of the world's largest organizations representing
specialists who treat the ear, nose, throat, and related structures
of the head and neck.”
At the Inspire booth, physicians reviewed the Inspire procedure
using new 3D visualization software and received updates on
technology enhancements across the entire Inspire portfolio,
including full-body MRI labeling, new lead technology designed for
the less invasive 2-incision procedure, and the new Inspire
SleepSync™ remote patient management platform.
In the scientific sessions, Inspire was featured prominently
throughout the meetings, with over 30 oral abstracts and posters
presented by leading otolaryngologists and sleep surgeons.
Posters and Presentations
- A Noninferiority Analysis of 3- versus 2- Incision Techniques
for HNS Implantation. (David T. Kent, MD et al.)
- Safety and efficacy profile for 2-incision technique is
noninferior to 3-incision technique
- Operative time is significantly decreased with the 2-incision
technique to 87 minutes
- Real-World Outcomes from Over 3 Million Nights of Upper Airway
Stimulation Therapy for CPAP Intolerant Obstructive Sleep Apnea.
(Jordan S. Weiner, MD et al.)
- First ever “big data” report of UAS outcomes
- Usage trends demonstrate high compliance to UAS despite history
of CPAP intolerance
- Outcomes of Surgical Upper Airway Stimulation in Hispanic vs
Non-Hispanic Populations. (Linda C. Magana, MD, Ryan J. Soose, MD,
et al., on behalf of the ADHERE Registry investigators)
- Analysis demonstrated no difference in UAS outcomes (e.g. AHI,
ESS, objective usage, and usage rates) in Hispanic patients versus
non-Hispanic patients
- The number of Hispanic participants in the ADHERE registry is
just 2.1% of the overall participants, which is significantly lower
than their proportion in the general U.S. population (18.7%)
- This analysis highlights the need to understand barriers to
care in receiving surgical UAS for patients of differing
socioeconomic, ethnic, and educational backgrounds
- Long-term Generator Replacement in Hypoglossal Nerve Stimulator
Clinical Trial Patients. (Ryan J. Soose, MD et al.)
- Longest follow-up study of hypoglossal nerve stimulation
- IPG replacements are safe and typically occur without
complications
- Outcomes (AHI, therapy usage) at 9 years are consistent with
5-year results
About ISSSThe ISSS is the world’s preeminent
organization dedicated to the surgical evaluation and treatment of
patients with sleep disorders. For more information, please visit
www.surgicalsleep.org.
About AAO-HNSFThe AAO-HNS (“the Academy”) is
one of the world's largest organizations representing specialists
who treat the ear, nose, throat, and related structures of the head
and neck. Head and neck surgeons diagnose and treat medical
disorders that are among the most common affecting patients of all
ages in the United States and around the world. Those medical
conditions include chronic ear disease, hearing and balance
disorders, hearing loss, sinusitis, snoring and sleep apnea,
allergies, swallowing disorders, nosebleeds, hoarseness, dizziness,
and tumors of the head and neck as well as intricate micro-surgical
procedures of the head and neck. The Academy represents
approximately 13,000 ENT surgeons. For more information, please
visit www.entnet.org.
About Inspire Medical SystemsInspire is a
medical technology company focused on the development and
commercialization of innovative, minimally invasive solutions for
patients with obstructive sleep apnea. Inspire’s proprietary
Inspire therapy is the first and only FDA-approved neurostimulation
technology that provides a safe and effective treatment for
moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit
www.inspiresleep.com.
Safe Harbor for Forward-Looking StatementsThis
press release may contain forward-looking statements.
Forward-looking statements involve inherent risks and
uncertainties, and important factors could cause actual results to
differ materially from those anticipated, including the factors
identified under the captions “Risk Factors” in Part I, Item 1A of
our Annual Report on Form 10-K for the fiscal year ended December
31, 2021, and as such factors may be updated from time to time in
our other filings with the SEC, which are accessible on the SEC’s
website at www.sec.gov and the Investors page of our website at
www.inspiresleep.com.
Investor and Media Contact:Ezgi YagciVice
President, Investor Relationsezgiyagci@inspiresleep.com
617-549-2443
Inspire Medical Systems (NYSE:INSP)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Inspire Medical Systems (NYSE:INSP)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024